Iimpawu zoMsebenzi
Umda wokufumanisa: 5ng/mL;
Uluhlu lomgca: 5.00～400.00 ng/mL;
I-coefficient yolungelelwaniso lomgca R ≥0.990;
Ukuchaneka: ngaphakathi kwe-batch CV ngu-≤15%;phakathi kweebhetshi iCV yi ≤20%;
Ukuchaneka: ukutenxa okunxulumeneyo kweziphumo zomlinganiselo akuyi kuba ngaphezu kwe-±15% xa i-calibrator yokuchaneka esemgangathweni ivavanywa.
1. Gcina i-detector buffer ku-2～30℃.Isithinteli sizinzile ukuya kwiinyanga ezili-18.
2. Gcina i-Aehealth Ferritin Rapid Quantitative test cassette kwi-2～30℃, ubomi beshelufu bufikelela kwiinyanga ezili-18.
3. Ikhasethi yovavanyo kufuneka isetyenziswe kwiyure enye emva kokuvula ipakethi.
I-ST2 ilungu le-Toll-like receptor/interleukin-1 (interleukin-1, IL-1) receptor superfamily.I-IL-33 yi-ligand yayo ethile esebenzayo kwaye ifihliwe yi-cardiomyocytes kunye ne-fibroblasts.Iimveliso ezimbini ze-gene expression: transmembrane ST2 (ST2L) kunye ne-sST2.I-ST2L iqulethe imimandla emithathu ye-extracellular immunoglobulin, ngelixa i-sST2 ayinayo i-transmembrane kunye ne-intracellular receptor domains.Bazibophezela kwi-ligand eqhelekileyo i-IL-33 kwaye badlale indima yezinto eziphilayo.I-ST2L kunye ne-IL-33 indlela yomqondiso ineempembelelo ze-cardiomyocyte ezifana ne-anti-cardiomyocyte hypertrophy, i-myocardial fibrosis kunye ne-anti-atherosclerosis.Xa umthwalo wentliziyo ukhula, ukukhutshwa kwe-sST2 kwanda, kwaye ukunyuka kwe-sST2 kuthintela i-IL-33 ukuba idibanise ne-ST2L, ngaloo ndlela ixhathisa umphumo we-cardioprotective ye-IL-33 / ST2L indlela yokubonisa.Kucingelwa ukuba i-sST2 ingaba ngumlamli we-pathogenic we-cardiomyocyte hypertrophy kunye ne-myocardial fibrosis.Ukuzimisela kobungakanani bamanqanaba e-sST2 kunokubonelela oogqirha ngesixhobo esichanekileyo sokuncedisa ekuvavanyeni ukuhluleka kwentliziyo.